Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?

Abstract excerpt

INTRODUCTION: Although symptom controls in asthmatic children can be achieved through compliant use of conventional medication, some children have uncontrolled severe persistent asthma, especially if they are allergic. For these children, omalizumab (approved by the EMA and FDA in children aged > 6 years) could be a therapeutic option. However, response to omalizumab varies from one child to another. Predictive...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-Asthmatic Agents
• Share to Cell Adhesion Molecules